Multiple ways of targeting APOBEC3-virion infectivity factor interactions for anti-HIV-1 drug development.
about
Structural model for deoxycytidine deamination mechanisms of the HIV-1 inactivation enzyme APOBEC3GFirst-in-class small molecule inhibitors of the single-strand DNA cytosine deaminase APOBEC3GCombinatorial RNA-based gene therapy for the treatment of HIV/AIDSStructural determinants of HIV-1 Vif susceptibility and DNA binding in APOBEC3FInhibition of a NEDD8 Cascade Restores Restriction of HIV by APOBEC3GAPOBEC3F and APOBEC3G inhibit HIV-1 DNA integration by different mechanisms.Identification of 81LGxGxxIxW89 and 171EDRW174 domains from human immunodeficiency virus type 1 Vif that regulate APOBEC3G and APOBEC3F neutralizing activity.Lentiviral Vif degrades the APOBEC3Z3/APOBEC3H protein of its mammalian host and is capable of cross-species activity.Identification of a critical T(Q/D/E)x5ADx2(I/L) motif from primate lentivirus Vif proteins that regulate APOBEC3G and APOBEC3F neutralizing activity.Long-term restriction by APOBEC3F selects human immunodeficiency virus type 1 variants with restored Vif functionRecombinant origin, contamination, and de-discovery of XMRVIdentification of specific determinants of human APOBEC3F, APOBEC3C, and APOBEC3DE and African green monkey APOBEC3F that interact with HIV-1 Vif.Small-molecule APOBEC3G DNA cytosine deaminase inhibitors based on a 4-amino-1,2,4-triazole-3-thiol scaffold.Requirement of HIV-1 Vif C-terminus for Vif-CBF-β interaction and assembly of CUL5-containing E3 ligaseAnalysis of human APOBEC3H haplotypes and anti-human immunodeficiency virus type 1 activity.Ex vivo gene therapy for HIV-1 treatment.The role of amino-terminal sequences in cellular localization and antiviral activity of APOBEC3B.The activity spectrum of Vif from multiple HIV-1 subtypes against APOBEC3G, APOBEC3F, and APOBEC3HRedoxal, an inhibitor of de novo pyrimidine biosynthesis, augments APOBEC3G antiviral activity against human immunodeficiency virus type 1.APOBEC3G restricts HIV-1 to a greater extent than APOBEC3F and APOBEC3DE in human primary CD4+ T cells and macrophages.Dispersed sites of HIV Vif-dependent polyubiquitination in the DNA deaminase APOBEC3F.Impact of H216 on the DNA binding and catalytic activities of the HIV restriction factor APOBEC3GNuclear import of APOBEC3F-labeled HIV-1 preintegration complexes.Catalytic activity of APOBEC3F is required for efficient restriction of Vif-deficient human immunodeficiency virus.A Comparison of Two Single-Stranded DNA Binding Models by Mutational Analysis of APOBEC3G.Moderate influence of human APOBEC3F on HIV-1 replication in primary lymphocytesAn amorphous silicon photodiode microfluidic chip to detect nanomolar quantities of HIV-1 virion infectivity factor.CBFβ stabilizes HIV Vif to counteract APOBEC3 at the expense of RUNX1 target gene expression.APOBEC Enzymes as Targets for Virus and Cancer Therapy.Fab-based inhibitors reveal ubiquitin independent functions for HIV Vif neutralization of APOBEC3 restriction factors.Viral subversion of APOBEC3s: Lessons for anti-tumor immunity and tumor immunotherapy.
P2860
Q24615413-68060C3F-E9D2-40DD-8375-7CDB6963B1A6Q24615552-82E1F5F6-1856-43B3-A814-2DFFA7AA918FQ26866145-7EF6DDDD-BA14-4BF7-BD52-52AE61F28766Q27680506-FFA97F24-8E80-483D-AC86-BFDF3F9C837AQ28484619-E467D45C-1E49-4A8C-B1E9-1BF6BAA28E09Q33826968-540A8006-F609-4582-9DAB-1284128D7819Q33877364-38FC838F-9DB3-4035-9FA0-5856716FE1E5Q34045987-9B92AD00-0506-441C-9E31-EED4DC24697DQ34055413-79ACA481-AC4C-4060-94FF-8DFC91FF6DC0Q34120768-9C45259B-79BD-46CA-AFC7-F9FDFF3A1AB0Q34289436-534273B5-56E7-45D5-83A3-D600D07B3A69Q34416665-7CED7E36-C461-4961-8854-5CBF20FEF5C0Q34488163-C9F66626-D526-45F7-84B8-4D8516983F22Q34695564-F5978AB3-095E-4905-999F-C4DF35D0B647Q34742607-1279B501-5621-48F9-9D27-62DAEE502DDBQ34982851-D01B933F-4A5B-4121-843D-06589E9CEFFEQ35192821-C8205E1E-70D4-4C25-BD52-8F1ECA1A3E16Q35666084-9515D4A6-0642-4062-8251-2E2986175376Q35682519-B7F8422B-42DE-45D6-9A13-86CEF20A8D46Q36506765-444DF34E-6D52-4DF5-91D7-72F8D6424118Q36698954-94766917-8E24-4A8D-8EFC-DB276670DBB4Q36911764-F2CB5651-A458-4156-AC26-493C7860C7A8Q37377405-44936031-A9B3-42A3-9A12-D0E8F2B4C9A9Q37599297-CE2EB6E1-45BB-4DBD-A2FD-4B72462A1B81Q39214613-83131100-AEAA-4831-BF0E-614EE3D79430Q41930366-C81FEAA4-CC68-4BB4-81A6-3FCE3FEF8469Q42212865-19C4CAE2-20C8-4C51-AD07-EA6B86149423Q43239447-00533702-CC96-4041-9F54-79730F211014Q45324625-7BE6DCB3-A32C-4E83-8CCA-CEB1E86C3BC4Q47229846-4179747B-97F0-448A-9FBE-B88DE099439CQ47568875-A2581BC0-0D24-4C9D-8D97-D8016F2003A2
P2860
Multiple ways of targeting APOBEC3-virion infectivity factor interactions for anti-HIV-1 drug development.
description
2009 nî lūn-bûn
@nan
2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Multiple ways of targeting APO ...... r anti-HIV-1 drug development.
@ast
Multiple ways of targeting APO ...... r anti-HIV-1 drug development.
@en
type
label
Multiple ways of targeting APO ...... r anti-HIV-1 drug development.
@ast
Multiple ways of targeting APO ...... r anti-HIV-1 drug development.
@en
prefLabel
Multiple ways of targeting APO ...... r anti-HIV-1 drug development.
@ast
Multiple ways of targeting APO ...... r anti-HIV-1 drug development.
@en
P2093
P2860
P1476
Multiple ways of targeting APO ...... or anti-HIV-1 drug development
@en
P2093
Jessica L Smith
Ryan C Burdick
P2860
P304
P356
10.1016/J.TIPS.2009.09.006
P577
2009-12-01T00:00:00Z